Vaccines Market Size & Share 2025 – 2034

Vaccines Market Size

The global vaccines market size was valued at USD 76.4 billion in 2024. The market is expected to grow from USD 78.9 billion in 2025 to USD 145.8 billion in 2034, at a CAGR of 7.1%. The market growth is primarily driven by the growing infectious diseases cases such as hepatitis, seasonal flu, and COVID-19 variations. These public health threats have significantly increased the demand for vaccines aimed at outbreak prevention.

Also, widespread public health initiatives promoting immunization, along with accelerated vaccine development efforts, are further propelling market expansion. According to a data reported by Boston Children’s Hospitals, around 3,000 cases of bacterial meningitis occur annually in the U.S., predominantly affecting infants, children, college students, and the elderly. These numbers highlight the ongoing need for meningitis vaccines to protect against bacterial infections.
 

The expansion of immunization programs, particularly in developing countries, reflects increased healthcare spending and global support. The growing popularity of combination vaccines designed to protect patients against multiple diseases through single doses is also contributing to vaccines development. The rising research efforts with continuous research and development activities are paving the way for new therapeutic vaccines targeting cancer, autoimmune disorders, and chronic diseases, creating new opportunities for innovation within the sector.
 

Further, the aging global population, with its heightened vulnerability to infectious diseases, continues to sustain vaccine demand. The market is also benefiting from expanding collaborations between public and private entities focused on vaccine research, development, and distribution.
 

Vaccines are biological preparations designed to induce active acquired immunity against specific infectious diseases. These formulations typically include components such as inactivated or attenuated pathogens, proteins, or genetic materials (like mRNA or subunits), which enable the immune system to recognize and combat disease-causing organisms upon future exposure.
 

Vaccines Market Trends

• Advancements in vaccine formulation and production efficiency are driving the global vaccine market growth. The development of mRNA technology, recombinant DNA techniques, and adjuvants has resulted in more effective, safer, and adaptable vaccines.
   
• These innovations aimed to facilitate rapid vaccine development against emerging diseases, as demonstrated during the COVID-19 pandemic. Also, the implementation of enhanced cold-chain logistics, scalable manufacturing processes, and automation has reduced production costs and increased output, improving global vaccine accessibility.
   
• The higher incidence rate of hepatitis and human papilloma virus that can lead to severe health conditions in case of improper diagnosis will drive the demand for preventive vaccination, thereby stimulating the market growth.
   
• As per the World Health Organization, nearly 1.5 million individuals are estimated to be affected with Hepatitis C viral infection every year globally. Thus, the availability of effective preventive vaccines offering immunity against these diseases will offer unprecedented growth opportunities to the market in the forthcoming years.
   
• Advancements in the technology helped to achieve milestones in the vaccine development including avian flu vaccine, nasal flu vaccine, therapeutic cancer vaccine and egg-free vaccine among others. Along with development and disease prevalence, the immunization programs and supportive initiatives by the government authorities to improve immunization coverage will positively impact the vaccines industry growth during the analysis period.
   
• Further, the growing collaboration between global health initiatives and public-private partnerships has streamlined regulatory approvals and distribution processes. These technological advancements are reshaping the vaccine industry, enhancing immunization efficiency and accessibility, which contributes to market growth and improved public health outcomes.
   

Vaccines Market Analysis

In 2021, the global market was valued at USD 139 billion. The following year, it saw a significant decrease to USD 105.3 billion and in 2023, the market decreases to USD 71 billion.
 

Based on vaccine type, the global market is segmented into subunit vaccines, toxoid vaccines, inactivated vaccines, live attenuated vaccines, and other vaccine types. The subunit vaccines segment dominated the market and was valued at USD 37.6 billion in 2024 and is poised to reach USD 70.7 billion by 2034, at a CAGR of 6.9%.
 

• The subunit vaccines are categorized into recombinant vaccines, conjugate vaccines and polysaccharide vaccines.
   
• The subunit vaccine expansion is due to their proven safety profile, as these vaccines incorporate specific part of a pathogen, typically proteins rather than the complete viruses or bacterium. Their targeted mechanism improves immune response rates while reducing side effects making them a preferred option.
   
• Also, the segment growth is primarily attributed to advantages of conjugate vaccines including T cell-dependent immune response. The conjugate vaccines offer long lasting immunity, improved memory and immune response, protection to toddlers and infants along with herd immunity.
   
• Therefore, with enhancements in vaccine technologies, the segment is anticipated to witness robust growth in the upcoming period.
   
• The manufacturing advantages through established DNA technology support efficient, cost-effective production processes which help in fueling its production capability.
   
• Furthermore, the recent global health events have increased the emphasis on vaccine safety, driving higher research and development (R&D) investments in subunit vaccines.
   

Based on disease type, the global vaccines market is categorized into viral diseases and bacterial diseases. The viral diseases segment accounted for the highest market share of 66.2% in 2024 and is poised to grow at a substantial rate during the analysis period.
 

• The viral disease segment is further categorized hepatitis, influenza, HPV, measles, mumps, and rubella (MMR), rotavirus, herpes zoster, COVID-19, and other viral diseases.
   
• The COVID-19 pandemic has significantly expanded vaccine development and global immunization initiatives, reinforcing the importance of viral disease prevention.
   
• The recent developments in vaccine production methods, including mRNA platforms and recombinant subunit vaccines, have improved response capabilities to viral outbreaks.
   
• The expansion of public health programs, immunization campaigns, and increased health awareness has resulted in higher vaccination rates, thereby strengthening the demand of viral disease vaccines.
   

Based on the age group, the global vaccines market is categorized into pediatric and adult. In 2024, the adult segment accounted for the largest share of 77.4% in the market and is anticipated to dominate the market throughout the forecast period at a CAGR of 7%.
 

• This population group is highly susceptible to various infectious diseases due to the undeveloped immunity system. Also, the heightened focus on preventive healthcare measures and understanding of immunization benefits has resulted in increased vaccine uptake among the adult population.
   
• Government programs and pharmaceutical company partnerships have enhanced vaccine distribution and coverage rates, thereby expanding its accessibility.
   
• Rising investments in the development of vaccines targeting adult-specific diseases, including sexually transmitted infections (like HPV in adults), respiratory diseases, and therapeutic vaccines for chronic illnesses such as cancers and autoimmune conditions, are broadening the vaccine landscape for adults.
   

Based on the end use, the global vaccines market is categorized by hospitals, specialty clinics, and other end users. In 2024, the hospitals segment accounted for the largest share of 50.1% in the market and is anticipated to reach USD 73.8 billion by 2034.
 

• The hospitals segment is further categorized into public and private hospitals. Hospitals are the central hub to primary care for patients seeking preventive measures, especially during outbreaks or routine immunization drives.
   
• These facilities offer reliable infrastructure, trained professionals, and access to cold-chain storage facilities for vaccine efficacy.
   
• Also, the mass immunization programs and managing specialized vaccines requiring medical supervision are highly facilitated by hospitals, thus strengthening its preference.
   
• Moreover, hospitals often operate within insurance-covered healthcare frameworks, allowing broader patient access to costly vaccines. Reimbursement policies through public health programs and private insurers encourage vaccine uptake in hospital settings.
   

In 2024, North America vaccines market accounted for the largest revenue of USD 32.3 billion and is projected to generate revenue of USD 59.3 billion by 2034, at a CAGR of 6.6% during the analysis period.
 

• North America's dominance in the global market is largely attributed to extensive government immunization initiatives, high public health awareness, and strong healthcare infrastructure.
   
• The region faces a high burden of infectious diseases, driving the need for robust vaccination programs. For example, according to the Hepatitis B Foundation, around 2.4 million individuals in the U.S. were living with Hepatitis B in 2021, prompting stronger vaccination measures.
   
• Similarly, HPV infections affect nearly 79 million Americans, leading to prioritization of HPV vaccination, especially due to its association with over 90% of cervical cancer cases and several other cancer types.
   
• This has driven substantial public health campaigns, school-based vaccination programs, and policy-level support, making HPV vaccines a critical component of preventive healthcare strategies in the U.S. and reinforcing overall market growth.
   

In 2024, the U.S. vaccines market accounted for USD 29.3 billion revenue from USD 27.4 billion in 2023.
 

• The strong R&D capabilities in mRNA and recombinant platforms are expected to support efficient vaccine development and disease response. These factors collectively positioned U.S. as a prominent country in the market.
   
• Regulatory frameworks that facilitate fast-track approvals and ensure safety along with government programs such as Vaccines for Children (VFC), and investments in pandemic preparedness that have improved vaccine access and uptake is anticipated to spur the country level market growth.
   
• Moreover, the implementation of the Healthcare Price Transparency Executive Order in 2025 is expected to increase affordability and access to vaccines, especially for low- and middle-income groups. Leading pharmaceutical companies like Pfizer, Moderna, and Johnson & Johnson play a pivotal role in ensuring supply chain continuity, both for routine immunizations and emergency responses.
   

Germany vaccines market is poised to achieve significant growth in the Europe market.
 

• Germany is positioned for significant growth within the European market due to its strong healthcare system, pharmaceutical innovation, and consistent public health investments.
   
• Key factors driving growth include continued R&D in advanced vaccine technologies such as mRNA and recombinant platforms, focused efforts to improve immunization coverage, and enhanced pandemic preparedness.
   
• Additionally, the integration of digital health/tools to track vaccination status and optimize delivery systems has improved operational efficiency.
   
• Collaborations with global manufacturers and active participation in EU-wide vaccine initiatives further strengthen the country's role in regional supply and innovation.  
   

Asia Pacific is poised to grow at a significant growth rate in the global vaccines market over the next few years.
 

• The Asia Pacific region is expected to grow at a substantial rate, driven by its large population base, increasing health awareness, and strengthening healthcare infrastructure. Countries such as China, India, Japan, and South Korea are investing heavily in vaccine development, distribution, and export capabilities.
   
• The region’s growth is supported by expanding government-led immunization programs, rising demand for adult and travel-related vaccines spurred by urbanization and global mobility, and strong domestic manufacturers like Serum Institute of India, Bharat Biotech, Sinovac, and SK Bioscience, which are enhancing production capacity and innovation.
   
• Additionally, countries in the region are increasingly prioritizing disease-specific vaccination strategies. For instance, with HPV infections becoming a growing concern, especially due to their established link to over 90% of cervical cancer cases, several Asia Pacific nations are integrating HPV vaccination into national immunization schedules, mirroring global trends seen in the U.S. and Europe.
   
• This focused approach to cancer prevention through vaccines further reinforces the region’s commitment to public health advancement and market expansion.
   

China is anticipated to grow significantly within the Asia Pacific vaccines market.
 

• China is poised for substantial growth in the Asia Pacific market, driven by its large population, strong regulatory framework, and expanding production infrastructure.
   
• The government’s focus on nationwide immunization through programs like the National Immunization Program (NIP), which covers over 95% of the population has significantly boosted vaccine demand.
   
• Strategic investments in biotechnology and advanced platforms, including mRNA, recombinant, and inactivated vaccines, are accelerating innovation and development. Established domestic manufacturers such as Sinovac and Sinopharm play a key role in ensuring supply stability, supported by state-backed distribution networks and export initiatives.
   
• Additionally, rising healthcare awareness, urbanization, and a growing burden of infectious and chronic diseases are contributing to market growth. These factors, combined with increased public health spending and infrastructure expansion, continue to strengthen China’s role as a key contributor to the region’s vaccine landscape.
   

Brazil is projected to witness significant growth in Latin America vaccines market in coming years.
 

• Brazil prominence was driven by its established healthcare infrastructure and policy framework. Brazil is one of the largest populated country boasting a strong public healthcare system (SUS) that supports the nationwide immunization programs. The National Immunization Program (PNI) ensures essential vaccines to reach population without cost barriers, maintaining high vaccination rates.
   
• Also, the presence of domestic vaccine manufacturers, including Fiocruz and Butantan Institute, reinforces Brazil's supply chain stability and minimizes import requirements.
   
• The implementation of COVID-19 vaccination programs has strengthened the vaccination infrastructure and improved cold chain capabilities.
   
• Therefore, the country’s systematic healthcare approach, which integrates health policies, manufacturing capabilities, and distribution networks, reinforces its position as a major growth market for vaccines in Latin America.
   

Saudi Arabia vaccines market is anticipated to grow in the Middle East and Africa market.
 

• Saudi Arabia is expected to witness strong growth in the Middle East and Africa market, driven by proactive government initiatives, rising public awareness of preventive healthcare, and strategic investments in healthcare infrastructure.
   
• The Vision 2030 healthcare modernization program has played a pivotal role in establishing comprehensive immunization protocols and expanding healthcare access. Efforts by the Ministry of Health, including widespread vaccination campaigns and digital communication strategies, have significantly improved vaccine awareness and acceptance.
   
• Simultaneously, the country is strengthening domestic vaccine manufacturing capabilities through collaborations with global pharmaceutical companies, enhancing supply chain resilience. Regulatory reforms mandating immunization for certain populations have further fueled vaccine demand.
   
• For example, the rise in international travel and the prevalence of infectious diseases have led to mandatory meningitis vaccination for pilgrims and visitors as of February 2025, boosting local production and procurement efforts.
   
• These advancements, supported by policy-driven reforms and technological enhancements, are positioning Saudi Arabia as a regional hub for vaccine distribution and opening new opportunities across public and private healthcare sectors.
   

Vaccines Market Share

The top 5-7 players in the global market accounted for nearly 70 - 75% of the share. The market demonstrates significant competition through rigorous research advancements, collaborations, and widespread immunization initiatives. The key players such as Pfizer, Merck, Sanofi, GSK and Moderna hold substantial share with extensive vaccine portfolios across pediatric, adult along with pandemic segments. The recent developments have positioned Moderna and Novavax as notable competitors through their technological platforms. In addition, Sanofi and AstraZeneca continue to maintain strong market positions through broad product offerings and international distribution networks.
 

The market landscape is intensified by R&D investments, regulatory developments, and expansion in adult and pediatric vaccine segments. The strategic collaborations, manufacturing agreements, and collaboration between public and private entities are further escalating the market demand.
 

Vaccines Market Companies

Few of the prominent players operating in the vaccines industry include:

• AstraZeneca
• Bharat Biotech
• Biofarma
• CSL Seqirus
• Emergent Biosolutions
• GlaxoSmithKline (GSK)
• Haffkine Bio-Pharmaceutical
• Merck
• Moderna
• Novavax
• Pfizer
• Sanofi
• Serum Institute of India
• Sinovac
• Valneva
• VBI Vaccines
   
• Pfizer holds a significant share with its established Prevnar pneumococcal vaccine series, Comirnaty COVID-19 vaccine, and Abrysvo RSV vaccine. The company's research pipeline, market presence, and partnership with BioNTech enhance its capabilities in pediatric, adult, and pandemic vaccine segments.
   
• Merck's market position centers on its Gardasil HPV vaccine, which remains essential in cancer prevention. The company's vaccine portfolio encompasses MMR, rotavirus, and pneumococcal products. Merck's development of RSV monoclonal antibodies and market expansion strategies reinforce its market presence.
   
• GSK maintains substantial market share in shingles, meningitis, and influenza vaccines. The introduction of Arexvy RSV vaccine and ongoing research initiatives demonstrate the company's emphasis on adult immunization. GSK's research investments and collaborative ventures support its position in vaccine development.
   

Vaccines Industry News

• In June 2025, Bharat Biotech and GSK entered into a collaborative agreement to advance the development of latter’s Shigella vaccine candidate altSonflex1-2-3. This agreement enables Bharat Biotech to lead further studies on the drug candidate including Phase 3 clinical trials, regulatory advancement and large-scale manufacturing. This collaborative effort aimed to strengthen the drug development and manufacturing capability expanding the accessibility of vaccines in the market.
   
• In May 2025, Moderna received the U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine, mNEXSPIKE (mRNA-1283). The vaccine is approved for two groups: adults aged 65 and older, and individuals between 12-64 years with underlying medical conditions. This new vaccine addresses variant protection requirements and improves distribution capabilities for vulnerable populations. The regulatory approval strengthened Moderna's position in mRNA vaccine development and reflects the expanding opportunities in the global market.
   
• In May 2025, Sanofi received the U.S. FDA grant MenQuadfi vaccine to be administered to infants from six weeks of age, establishing it as the first meningococcal vaccine for this demographic. The vaccine, which holds existing approval for individuals aged two years and above, targets four primary meningococcal bacterial strains. This regulatory approval broadens Sanofi's pediatric vaccine portfolio while addressing the medical need for early-age immunization, thereby expanding market reach and disease prevention capabilities.
   

The vaccines market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021-2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Subunit vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • Polysaccharide vaccines
• Toxoid vaccines
• Inactivated vaccines
• Live attenuated vaccines
• Other vaccine types

Market, By Disease Type

• Viral diseases
  • Hepatitis
  • Influenza
  • HPV
  • Measles, mumps, and rubella (MMR)
  • Rotavirus
  • Herpes zoster
  • Covid-19
  • Other viral diseases
• Bacterial diseases
  • Meningococcal diseases
  • Pneumococcal diseases
  • DPT
  • Other bacterial diseases

Market, By Age Group

• Pediatric
• Adult

Market, By End Use

• Hospitals
  • Public
  • Private
• Specialty clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE